Biochemical and toxicological evaluation of nano-heparins in cell functional properties, proteasome activation and expression of key matrix molecules

Toxicology Letters

Volumn 240, Issue 1, 2016, Pages 32-42

  Piperigkou, Zoi ^a,b   Karamanou, Konstantina ^a,b   Afratis, Nikolaos A ^a   Bouris, Panagiotis ^a   Gialeli, Chrysostomi ^a   Belmiro, Celso L R ^c   Pavão, Mauro S G ^c   Vynios, Dimitrios H ^a   Tsatsakis, Aristidis M ^d  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Ascidian; Breast cancer; Extracellular matrix; Heparin; Pharmacological targeting; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE 14; PLASMINOGEN ACTIVATOR; PROTEASOME; PROTEOGLYCAN; SCLEROPROTEIN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; NANOMATERIAL; PROTEASOME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASCIDIACEA; BIOCHEMICAL ANALYSIS; BIOLOGICAL ACTIVITY; BREAST CANCER CELL LINE; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTESTINE; NONHUMAN; PIG; PRIORITY JOURNAL; PROTEIN EXPRESSION; STYELA PLICATA; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; EXTRACELLULAR MATRIX; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR MATRIX; HEPARIN; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; NANOSTRUCTURES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84945156915     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2015.10.005     Document Type: Article

References (53)

1. Afratis N., Gialeli C., Nikitovic D., Tsegenidis T., Karousou E., Theocharis A.D., Pavao M.S., Tzanakakis G.N., Karamanos N.K. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 2012, 279:1177-1197.
2. Ataie-Kachoie P., Pourgholami M.H., Richardson D.R., Morris D.L. Gene of the month: interleukin 6 (IL-6). J. Clin. Pathol. 2014, 67:932-937.
3. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M.G., Pecciarini L., Angelo Mauri F., Veronese S., Caffo O., Lucenti A., Palma P.D., Galligioni E., Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003, 98:474-483.
4. Barbouri D., Afratis N., Gialeli C., Vynios D.H., Theocharis A.D., Karamanos N.K. Syndecans as modulators and potential pharmacological targets in cancer progression. Front. Oncol. 2014, 4(4).
5. Belmiro C.L., Castelo-Branco M.T., Melim L.M., Schanaider A., Elia C., Madi K., Pavao M.S., de Souza H.S. Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J. Biol. Chem. 2009, 284:11267-11278.
6. Block K., Boyer T.G., Yew P.R. Phosphorylation of the human ubiquitin-conjugating enzyme, CDC34, by casein kinase 2. J. Biol. Chem. 2001, 276:41049-41058.
7. Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb. Res. 2010, 125(Suppl. (2)):S66-S71.
8. Cardilo-Reis L., Cavalcante M.C., Silveira C.B., Pavao M.S. In vivo antithrombotic properties of a heparin from the oocyte test cells of the sea squirt Styela plicata (Chordata-Tunicata). Braz. J. Med. Biol. Res. 2006, 39:1409-1415.
9. Cavalcante M.C., Allodi S., Valente A.P., Straus A.H., Takahashi H.K., Mourao P.A., Pavao M.S. Occurrence of heparin in the invertebrate styela plicata (Tunicata) is restricted to cell layers facing the outside environment. An ancient role in defense?. J. Biol. Chem. 2000, 275:36189-36196.
10. Chalkiadaki G., Nikitovic D., Berdiaki A., Katonis P., Karamanos N.K., Tzanakakis G.N. Heparin plays a key regulatory role via a p53/FAK-dependent signaling in melanoma cell adhesion and migration. IUBMB Life 2011, 63:109-119.
11. Chalkiadaki G., Nikitovic D., Katonis P., Berdiaki A., Tsatsakis A., Kotsikogianni I., Karamanos N.K., Tzanakakis G.N. Low molecular weight heparin inhibits melanoma cell adhesion and migration through a PKCa/JNK signaling pathway inducing actin cytoskeleton changes. Cancer Lett. 2011, 312:235-244.
12. Choi Y., Chung H., Jung H., Couchman J.R., Oh E.S. Syndecans as cell surface receptors: Unique structure equates with functional diversity. Matrix Biol. 2011, 30:93-99.
13. Chondrogianni N., Gonos E.S. Proteasome activation as a novel antiaging strategy. IUBMB Life 2008, 60:651-655.
14. Couchman J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26:89-114.
15. Dreger H., Westphal K., Weller A., Baumann G., Stangl V., Meiners S., Stangl K. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc. Res. 2009, 83:354-361.
16. Du Z.X., Yan Y., Zhang H.Y., Liu B.Q., Gao Y.Y., Niu X.F., Meng X., Wang H.Q. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells. J. Clin. Endocrinol. Metab. 2011, 96:E763-E771.
17. Fears C.Y., Woods A. The role of syndecans in disease and wound healing. Matrix Biol. 2006, 25:443-456.
18. Fulda S., Debatin K.M. Apoptosis signaling in tumor therapy. Ann. N. Y. Acad. Sci. 2004, 1028:150-156.
19. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278:16-27.
20. Glickman M.H., Adir N. The proteasome and the delicate balance between destruction and rescue. PLoS Biol. 2004, 2:E13.
21. Heikkila K., Ebrahim S., Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 2008, 44:937-945.
22. Iozzo R.V., Karamanos N. Proteoglycans in health and disease: emerging concepts and future directions. FEBS J. 2010, 277:3863.
23. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010, 277:3864-3875.
24. Kapeta S., Chondrogianni N., Gonos E.S. Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J. Biol. Chem. 2010, 285:8171-8184.
25. Karamanos N.K., Syrokou A., Vanky P., Nurminen M., Hjerpe A. Determination of 24 variously sulfated galactosaminoglycan- and hyaluronan-derived disaccharides by high-performance liquid chromatography. Anal. Biochem. 1994, 221:189-199.
26. Karamanos N.K., Tzanakakis G.N. Glycosaminoglycans: from cellular glue to novel therapeutical agents. Curr. Opin. Pharmacol. 2012, 12:220-222.
27. Kemp M.M., Linhardt R.J. Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:77-87.
28. Kousidou O., Berdiaki A., Kletsas D., Zafiropoulos A., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol. Oncol. 2008, 2:223-232.
29. Kozlowski E.O., Pavao M.S., Borsig L. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J. Thromb. Haemost. 2011, 9:1807-1815.
30. Kozlowski E.O., Pavao M.S. Effect of sulfated glycosaminoglycans on tumor invasion and metastasis. Front. Biosci. 2011, 3:1541-1551.
31. Kwak M.K., Wakabayashi N., Greenlaw J.L., Yamamoto M., Kensler T.W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol. 2003, 23:8786-8794.
32. Liang Y., Kiick K.L. Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications. Acta Biomater. 2014, 10:1588-1600.
33. Linhardt R.J., Toida T. Role of glycosaminoglycans in cellular communication. Acc. Chem. Res. 2004, 37:431-438.
34. Matsuda K., Maruyama H., Guo F., Kleeff J., Itakura J., Matsumoto Y., Lander A.D., Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001, 61:5562-5569.
35. Mizumoto S., Sugahara K. Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors. FEBS J. 2013, 280:2462-2470.
36. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
37. Niers T.M., Klerk C.P., DiNisio M., Van Noorden C.J., Buller H.R., Reitsma P.H., Richel D.J. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit. Rev. Oncol. Hematol. 2007, 61:195-207.
38. Nikitovic D., Corsini E., Kouretas D., Tsatsakis A., Tzanakakis G. ROS-major mediators of extracellular matrix remodeling during tumor progression. Food Chem. Toxicol. 2013, 61:178-186.
39. Nurunnabi M., Khatun Z., Moon W.C., Lee G., Lee Y.K. Heparin based nanoparticles for cancer targeting and noninvasive imaging. Quant. Imaging Med. Surg. 2012, 2:219-226.
40. Reinstein E., Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann. Intern. Med. 2006, 145:676-684.
41. Santos J.C., Mesquita J.M., Belmiro C.L., da Silveira C.B., Viskov C., Mourier P.A., Pavao M.S. Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis. Thromb. Res. 2007, 121:213-223.
42. Shi Z.D., Wang H., Tarbell J.M. Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen. PLoS One 2011, 6:e15956.
43. Skandalis S.S., Aletras A.J., Gialeli C., Theocharis A.D., Afratis N., Tzanakakis G.N., Karamanos N.K. Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Curr. Mol. Med. 2012, 12:1068-1082.
44. Suchi K., Fujiwara H., Okamura S., Okamura H., Umehara S., Todo M., Furutani A., Yoneda M., Shiozaki A., Kubota T., Ichikawa D., Okamoto K., Otsuji E. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res. 2011, 31:67-75.
45. Tanaka K. Proteasomes: structure and biology. J. Biochem. 1998, 123:195-204.
46. Theocharis A.D., Gialeli C., Bouris P., Giannopoulou E., Skandalis S.S., Aletras A.J., Iozzo R.V., Karamanos N.K. Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J. 2014, 281:5023-5042.
47. Theocharis A.D., Skandalis S.S., Neill T., Multhaupt H.A., Hubo M., Frey H., Gopal S., Gomes A., Afratis N., Lim H.C., Couchman J.R., Filmus J., Sanderson R.D., Schaefer L., Iozzo R.V., Karamanos N.K. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. BBA 2015, 1855:276-300.
48. Theocharis A.D., Skandalis S.S., Tzanakakis G.N., Karamanos N.K. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010, 277:3904-3923.
49. Tilghman R.W., Cowan C.R., Mih J.D., Koryakina Y., Gioeli D., Slack-Davis J.K., Blackman B.R., Tschumperlin D.J., Parsons J.T. Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS One 2010, 5:e12905.
50. Weyers A., Linhardt R.J. Neoproteoglycans in tissue engineering. FEBS J. 2013, 280:2511-2522.
51. Xian X., Gopal S., Couchman J.R. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 2010, 339:31-46.
52. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12:375-391.
53. Zittermann S.I., Capurro M.I., Shi W., Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int. J. Cancer 2010, 126:1291-1301.